Immunogen, Inc. (NASDAQ:IMGN) shares traded 0.20% higher at $29.71 on Wall Street last session.
In accordance with the data, 14 analysts cover Immunogen, Inc. (NASDAQ:IMGN). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $31.26 and a low of $19.00, we find $31.00. Given the previous closing price of $29.65, this indicates a potential upside of 4.55 percent. IMGN stock price is now 71.00% away from the 50-day moving average and 116.27% away from the 200-day moving average. The market capitalization of the company currently stands at $7.95B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
It has been rated a hold by 11 analysts and a buy by 3. Brokers who have rated the stock have averaged $29.48 as their price target over the next twelve months.
With the price target enhanced from $25 to $31, Guggenheim Downgraded its rating from Buy to Neutral for Immunogen, Inc. (NASDAQ: IMGN).
In other news, Wingrove Theresa, SVP OF REGULATORY AFFAIRS sold 164,424 shares of the company’s stock on Nov 30. The stock was sold for $4,760,075 at an average price of $28.95. Upon completion of the transaction, the SVP OF REGULATORY AFFAIRS now directly owns 2,811 shares in the company, valued at $83514.81. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, Director Peterson Kristine sold 20,000 shares of the business’s stock. A total of $578,000 was realized by selling the stock at an average price of $28.90. Insiders disposed of 4,269,035 shares of company stock worth roughly $126.83 million over the past 1 year. A total of 2.56% of the company’s stock is owned by insiders.
Immunogen, Inc. (NASDAQ: IMGN) opened at $29.80 on Tuesday. During the past 12 months, Immunogen, Inc. has had a low of $3.61 and a high of $29.93. As of last week, the company has a debt-to-equity ratio of 0.20, a current ratio of 5.70, and a quick ratio of 5.65. The fifty day moving average price for IMGN is $17.37 and a two-hundred day moving average price translates $13.74 for the stock.
The latest earnings results from Immunogen, Inc. (NASDAQ: IMGN) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.1, beating analysts’ expectations of $0.04 by 0.06. This compares to -$0.31 EPS in the same period last year. The net profit margin was -25.56% and return on equity was -19.88% for IMGN. The company reported revenue of $113.42 million for the quarter, compared to $15.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 637.72 percent. For the current quarter, analysts expect IMGN to generate $129.47M in revenue.
